Cellectis
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Cellectis and buy or sell other stocks, ETFs, and their options commission-free!About CLLS
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J.
CEOAndré Choulika
CEOAndré Choulika
Employees229
Employees229
HeadquartersParis, Ile-de-France
HeadquartersParis, Ile-de-France
Founded2000
Founded2000
Employees229
Employees229
CLLS Key Statistics
Market cap262.27M
Market cap262.27M
Price-Earnings ratio-5.39
Price-Earnings ratio-5.39
Dividend yield—
Dividend yield—
Average volume35.34K
Average volume35.34K
High today$3.63
High today$3.63
Low today$3.54
Low today$3.54
Open price$3.54
Open price$3.54
Volume43.06K
Volume43.06K
52 Week high$5.48
52 Week high$5.48
52 Week low$1.33
52 Week low$1.33
CLLS News
TipRanks 1d
Cellectis initiated with an Overweight at BarclaysBarclays initiated coverage of Cellectis (CLLS) with an Overweight rating and $9 price target The company is focused on the development of allogenic CAR-T thera...
Investing.com 1d
Barclays initiates Cellectis stock with overweight, $9 target - Investing.com...
Analyst ratings
88%
of 8 ratingsBuy
87.5%
Hold
12.5%
Sell
0%
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.